Division of Gastroenterology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea; Department of Medicine, Yonsei University Graduate School, Seoul, Republic of Korea.
Department of Radiology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Pancreatology. 2020 Jul;20(5):952-959. doi: 10.1016/j.pan.2020.05.017. Epub 2020 May 27.
Venous invasion is not included in the pancreatic ductal adenocarcinoma (PDAC) staging, and its correlation with prognosis remains unclear. We evaluated the prognostic impact of radiographic portal/superior mesenteric vein (PV/SMV) invasion, and its possibility of complementing T staging.
We identified patients with non-metastatic PDAC using our institutional cohort, and divided them according to PV/SMV invasion at imaging, defined as >180-degree tumor-vessel interface or contour deformity. We conducted Cox proportional hazard regression, and compared survival in the original and 1:1 propensity score matched datasets.
We identified 454 patients [PV/SMV(+): 172; PV/SMV(-): 282]. In the multivariate analysis, PV/SMV invasion, age (≥70 years), performance status, tumor size (2-4, >4 cm), lymph nodes >4, and arterial invasion was correlated with prognosis. The PV/SMV(+) group had a shorter overall survival (OS) than the PV/SMV(-) group in the original (14.4 vs. 20.9 months; P < 0.001) and matched datasets (14.3 vs. 17.2 months; P = 0.009). Among patients without arterial invasion (cT1-cT3), the PV/SMV(+) group had a shorter OS (15.9 vs. 21.2 months; P = 0.002). Moreover, their OS did not differ from that of patients with arterial invasion (cT4) (15.9 vs. 14.4 months; P = 0.907). Patients with vessel (artery/vein) invasion had a shorter OS than those without vessel invasion (14.5 vs. 21.2 months; P < 0.001).
Radiographic PV/SMV invasion in non-metastatic PDAC was correlated with a poor prognosis. It could identify a group with shorter OS among patients without arterial invasion (cT1-cT3). It is suggested that inclusion of PV/SMV invasion in clinical T4 criteria should be considered.
静脉侵犯并未纳入胰腺导管腺癌(PDAC)分期,其与预后的相关性尚不清楚。我们评估了影像学门静脉/肠系膜上静脉(PV/SMV)侵犯的预后影响,并探讨了其补充 T 分期的可能性。
我们通过机构队列确定了非转移性 PDAC 患者,并根据影像学检查中是否存在 PV/SMV 侵犯进行分组,定义为肿瘤-血管界面>180 度或轮廓变形。我们进行了 Cox 比例风险回归,并比较了原始数据集和 1:1 倾向评分匹配数据集的生存情况。
共纳入 454 例患者[PV/SMV(+): 172 例;PV/SMV(-): 282 例]。多因素分析显示,PV/SMV 侵犯、年龄(≥70 岁)、体力状况、肿瘤大小(2-4 cm、>4 cm)、淋巴结>4 个、动脉侵犯与预后相关。在原始数据集和匹配数据集(14.3 个月 vs. 17.2 个月;P=0.009)中,PV/SMV(+)组的总生存(OS)均短于 PV/SMV(-)组(14.4 个月 vs. 20.9 个月;P<0.001)。在无动脉侵犯(cT1-cT3)的患者中,PV/SMV(+)组的 OS 更短(15.9 个月 vs. 21.2 个月;P=0.002)。此外,其 OS 与有动脉侵犯(cT4)的患者无差异(15.9 个月 vs. 14.4 个月;P=0.907)。有血管(动脉/静脉)侵犯的患者 OS 短于无血管侵犯的患者(14.5 个月 vs. 21.2 个月;P<0.001)。
非转移性 PDAC 中影像学门静脉/肠系膜上静脉侵犯与预后不良相关。在无动脉侵犯(cT1-cT3)的患者中,它可以识别出一组 OS 更短的患者。建议考虑将 PV/SMV 侵犯纳入临床 T4 标准。